Resolution criteria

This market will resolve to "Yes" if Vinay Prasad ceases to hold his position as the director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) by December 31, 2025. The market will resolve to "No" if he remains in this role through the end of 2025. Official announcements from the FDA or reputable news outlets will serve as the primary sources for resolution.

Background

Vinay Prasad, an oncologist and former professor at the University of California, San Francisco, was appointed as the director of the FDA's CBER in May 2025. In this role, he oversees the regulation of biologic products, including vaccines and gene therapies. Prasad has been known for his critical views on certain FDA policies and COVID-19 mandates. (investing.com)

Considerations

Prasad's appointment has been met with mixed reactions. While some praise his commitment to scientific rigor, others express concern that his critical stance on previous FDA decisions may lead to stricter regulatory processes. (ajmc.com) Additionally, his recent promotion to the FDA's chief medical and science officer further solidifies his influence within the agency. (statnews.com) Traders should monitor any developments or controversies that could impact his tenure.